logo
Dirty habit followed by 18million Americans TRIPLES the risk of getting cancer

Dirty habit followed by 18million Americans TRIPLES the risk of getting cancer

Daily Mail​4 days ago
People who frequently use marijuana more than triple their risk of developing oral cancer, a new study found.
About half of US adults say they have ever tried marijuana, with about 17.7million suffering from symptoms of cannabis use disorder (CUD).
The condition requires a formal diagnosis after fulfilling several criteria, such as using the drug despite the negative impacts it has on a person's life and relationships.
University of California, San Diego researchers followed 45,000 people, some with cannabis use disorder, for five years. They discovered that daily smokers were 3.25 times more likely to develop oral cancer than those without the disorder.
Dr Raphael Cuomo, an anesthesiology professor at UC San Diego School of Medicine who led the analysis, said: 'Cannabis smoke contains many of the same carcinogenic compounds found in tobacco smoke, which have known damaging effects on the epithelial tissue that lines the mouth.'
Cannabis smoke packs a heavy load of toxic chemicals and carcinogens, about 2,600 of them, similar to tobacco smoke.
But researchers are only recently getting a fuller understanding of what those chemicals are. They now know that marijuana smoke contains hundreds of polycyclic aromatic hydrocarbons (PAHs), benzene, and ammonia.
These chemicals adhere to mucus membranes in the mouth, enabling carcinogens to seep into oral tissue. Meanwhile, THC, the psychoactive chemical in marijuana, can suppress crucial immune system pathways that would typically patrol for, and kill, those rogue cells.
Of the more than 45,000 patients included in the study, 949 had cannabis use disorder.
The group that did not smoke or smoked only occasionally remained either weed free or only occasional users over the five-year study. Over 97 percent were still abstinent or infrequent users by the time researchers followed up.
During the study, 106 patients were diagnosed with oral cancer. Among people without CUD, the rate of oral cancer was 0.23 percent, which matches general population rates.
However, among participants with CUD, 0.74 percent developed oral cancer.
Oral cancer includes cancerous growths that develop in the mouth and throat, including the lips, tongue, gums, the floor of the mouth and the roof of the mouth.
About one in 59 men and 1 in 139 women will develop oral cancer at some point in their lives.
Oral cancers account for about three percent of cancers diagnosed in the US every year, with about 58,500 diagnoses and 12,250 deaths annually.
Researchers said their findings will have implications for cancer screening practices in primary care and mental health settings, as patients with CUD often present with overlapping social and behavioral risk factors, including tobacco use, alcohol use, and a lower likelihood of engaging in preventive healthcare.
People with CUD who were also tobacco users were 6.24 times more likely to get oral cancer. Age also played a role, with each additional year of age increasing cancer risk by about four times per year.
Like tobacco smokers, marijuana smokers see damage to their lung and throat cells, leading to abnormal cell growth that can cause cancer and tissue changes.
Those effects can occur in people who are not tobacco smokers, though, indicating that marijuana smoke can be just as harmful on its own as cigarette smoke.
Dr Cuomo said: 'These findings add to a growing body of evidence suggesting that chronic or problematic cannabis use may contribute to cancer risk in tissues exposed to combustion products.'
Their findings were published in the journal Preventive Medicine Reports.
In the United States, marijuana is fully legal for recreational and medicinal use in 29 states. It is entirely illegal in four states.
The majority of the public, about 88 percent, supports legalization, according to the Pew Research Center. But public health experts are raising concerns over potential long-term effects, of which scientists still do not have a complete understanding.
In June, University of California researchers reviewed 24 studies involving 200million people to investigate the relationship between weed and cardiovascular disease, stroke and acute coronary syndrome (ACS) - a group of heart conditions in which there is reduced or blocked blood flow to the heart, such as a heart attack.
They found there was a 29 percent higher risk of ACS among cannabis users, a 20 percent higher risk for stroke and double the risk of dying from cardiovascular disease, which includes coronary artery disease, heart failure and irregular heartbeats.
Last month, findings from an FDA-run clinical trial were released, investigating dangerous liver enzyme spikes in people who consumed cannabis.
The results showed that eight users of CBD, the substance derived from the hemp plant that's free of the psychoactive chemical THC, developed enzyme spikes above the safe threshold, raising the risk of chronic liver damage or failure.
Seven people dropped out due to liver concerns between weeks three and four.
However, everyone's liver tests normalized after quitting CBD.
Meanwhile, regular use of potent cannabis in adolescence has been linked to long-term changes in brain structure, particularly in the prefrontal cortex, the region responsible for decision-making, emotional regulation, and impulse control.
This is also the age when many psychotic disorders first appear.
THC may trigger schizophrenia or psychotic episodes in individuals with genetic predispositions.
A 2022 review by University of Bath researchers, which analyzed 20 studies involving 120,000 people, found users of high-potency cannabis were four times more likely to develop addiction and three to five times more likely to suffer a psychotic break compared to those using lower-potency strains.
Earlier this year, a report in JAMA Network Open found that emergency room visits in Ontario, Canada, linked to schizophrenia in marijuana users tripled after legalization.
Between 2006 and 2022, the rate of schizophrenia among those with cannabis use disorder climbed from four percent to over 10 percent. In contrast, just 0.6 percent of non-users developed the condition.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novo Nordisk expands lawsuits against weight-loss drug compounders
Novo Nordisk expands lawsuits against weight-loss drug compounders

Reuters

time2 hours ago

  • Reuters

Novo Nordisk expands lawsuits against weight-loss drug compounders

Aug 5 (Reuters) - Danish drugmaker Novo Nordisk ( opens new tab said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic. The new lawsuits target pharmacies and telehealth companies producing compounded versions of semaglutide "under the fake guise of personalization", Novo said, without naming the companies. Shares of major telehealth firm Hims & Hers (HIMS.N), opens new tab extended losses to fall nearly 13% in afternoon trade. It had earlier reported weaker-than-expected quarterly revenue. A Reuters search of legal filings found some cases filed by Novo in California dated Aug. 4 but none regarding San Francisco-based Hims. Hims was not immediately available for comment. Compounders copy brand-name medicines that are in short supply by combining, mixing or altering drug ingredients to meet demand. These companies were briefly allowed to produce hundreds of thousands of compounded doses of Novo's obesity and diabetes drugs when the Food and Drug Administration said they were in short supply. When the agency later banned the sale of these copies, Hims and Hers shifted to creating versions of semaglutide in personalized doses not accessible through the branded manufacturers. Novo's lawsuits allege that telehealth providers violate state corporate practice of medicine laws by improperly influencing doctors' decisions and steering patients toward knockoff compounded "semaglutide" under the guise of personalized medicine. In reality, these are knockoffs that have not been approved as safe and effective and are often made with illicit foreign active pharmaceutical ingredients (API), Novo said. It did not immediately respond to a Reuters query on which companies were being named in the lawsuit.

Titan sub firm used 'intimidation tactics' and 'critically flawed' safety practices, Coast Guard report finds
Titan sub firm used 'intimidation tactics' and 'critically flawed' safety practices, Coast Guard report finds

BBC News

time3 hours ago

  • BBC News

Titan sub firm used 'intimidation tactics' and 'critically flawed' safety practices, Coast Guard report finds

Titan 'like working on a high-school project', engineering director sayspublished at 18:40 British Summer Time The former director of engineering at OceanGate has said the engineering team was mostly made up of "young, inexperienced individuals", which led to "significant gaps in capability", according to the US Coast Guard report. He described the Titan as similar to a "high school project". Talking about the team's morale, the former director also told investigators that many employees were unhappy in their roles and "ill-equipped to tackle the complexities of designing a sophisticated deep-sea submersible".

Ozempic to Mounjaro - what are the weight loss injections and what were they designed to do?
Ozempic to Mounjaro - what are the weight loss injections and what were they designed to do?

Sky News

time5 hours ago

  • Sky News

Ozempic to Mounjaro - what are the weight loss injections and what were they designed to do?

Drugs designed to treat diabetes and repurposed as miracle diet aids have taken over TikTok - and Hollywood. The weight loss caused by these weekly injectables is rapid and previously unattainable, people boast, showing off newly svelte bodies. But what are these drugs, how do they work - and what were they originally designed to do? Ozempic, Wegovy, Mounjaro - what are they? Let's start with the most well-known of the trio: Ozempic. Ozempic blew up in 2022 - if media reports from the US were to be believed, every pound dropped in LA was probably thanks to the "miracle" injectable drug. What started as the preserve of A-listers and the Hollywood elite quickly grew in popularity. The drug's generic name is semaglutide. This is the same as Wegovy, which has been licensed as a weight loss drug in the UK and is now available on the NHS. Wegovy has a slightly higher dosage and is designed for weight loss, while Ozempic's primary purpose was as a diabetes treatment (more on that later). Mounjaro - also known by its generic name tirzepatide - is the newer kid on the block. Like Ozempic and Wegovy, it suppresses the appetite and lengthens the amount of time food stays in the stomach, leading to weight loss - at least for as long as you carry on taking it. In 2022, the US Food and Drink Administration (FDA) fast-tracked approval of the drug to treat obesity after a study showed it helped people lose more than 20% of their bodyweight. Mounjaro was supposed to be available through GP surgeries and other community services in the UK from 23 June. But at the start of August, Sky News research revealed only eight of 42 NHS Integrated Care Boards (ICBs) in England had started providing treatment to patients, and many of the rest unable to guarantee when it would be available. 3:31 From diabetes drug to diet pill Ozempic and Mounjaro were both developed as treatments for type 2 diabetes. The drugs, which come as weekly injections, lower blood sugar by increasing insulin production when your blood sugar is rising and helping prevent your liver making and releasing too much sugar. So how do they cause weight loss? Both semaglutide and tirzepatide work by mimicking the hormone, GLP-1 (glucagon-like peptide one), to manage hunger and slow down digestion. Tirzepatide - Mounjaro - is a dual-acting drug and also mimics the hormone GIP (glucose-dependent insulinotropic polypeptide). In terms of weight loss, in clinical trials people lost up to 20% of their body weight on tirzepatide and 15% on semaglutide. Researchers have also found the weight loss jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose. They sound like miracle drugs for people wanting to lose weight - what's the catch? There are a few downsides. First off, the listed side effects: nausea, vomiting and diarrhoea, bad enough for about 5% of people in the semaglutide trial to stop taking it and 6-7% in the tirzepatide trial. People in the semaglutide trial also experienced problems with gallstones. The drugs also carry serious risks including kidney failure, pancreatitis and thyroid cancer. Another downside has been dubbed "Ozempic face". Facial ageing is a side effect of sudden weight loss as people find the skin on their face sagging where once it was plump. The drugs also only work for as long as you carry on taking them, and people have reported gaining back all the weight they lost after stopping the drug - either out of choice or because of a supply shortage. In August, the National Institute for Health and Care Excellence (NICE) - the body that provides guidance on the use of new drugs - said that people coming off the drugs should be offered "structured advice and follow-up support" to help prevent weight gain. This includes being monitored by the NHS for at least a year after completing treatment and support to help build "long-term behavioural habits, use self-monitoring tools, and draw on wider support - from online communities to family-led interventions and local activities". Shortages for diabetics Perhaps a bigger conversation than side effects for individuals is around the impact on people who rely on these treatments, now they've exploded in popularity as a weight loss quick-fix. While intended for diabetics, Ozempic and Mounjaro are prescribed "off-label" in the US to people wanting to shed weight. The drugs faced widespread shortage last year, with reports of diabetics having to drive from pharmacy to pharmacy in search of stock because of the high demand. Links to cancer prevention Research has suggested weight loss jabs, officially GLP-1 receptor agonists, could almost halve the risk of obesity-related cancers. The study, published in the journal eClinicalMedicine, was presented at the European Congress on Obesity in Malaga. It found that there were similar rates of obesity -related cancer among patients treated with the injections and those given weight loss, or bariatric, surgery. Dr Yael Wolff Sagy, the study's co-lead author from Clalit Health Services in Tel-Aviv, Israel, said a "direct effect" of the injections was that they were found "to be 41% more effective at preventing obesity-related cancer". "We do not yet fully understand how GLP-1s work," she said. "But this study adds to the growing evidence showing that weight loss alone cannot completely account for the metabolic, anti-cancer, and many other benefits that these medications provide." Co-lead Professor Dror Dicker, from Hasharon Hospital, Rabin Medical Centre in Israel, suggested the protective effects of the drugs "likely arise from multiple mechanisms, including reducing inflammation". He added further research was needed "to make sure that these drugs do not increase the risk for non-obesity-related cancers". Being overweight or obese is the second biggest cause of cancer in the UK, causing more than one in 20 cancer cases, according to the NHS. Are they available in the UK? An estimated 1.5 million people are taking weight loss jabs in the UK, the vast majority of whom pay for them privately. Ozempic is available in the UK for type 2 diabetes patients with a prescription. Wegovy and Mounjaro is available to NHS patients, but only through specialist weight management services. Over the next three years, around 240,000 people with the "greatest need" are expected to receive Mounjaro through the NHS. However, Sky News research into Wegovy and Mounjaro shows delays in the rollout of both weight loss jabs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store